Genedata Profiler 15.0 Release
Simplifying Translational and Clinical Data Access and Analysis with Genedata Profiler
Another big step towards the digitalization of translational and clinical research. With the release of Genedata Profiler 15.0, scientists will now be able to uncover actionable insights through an intuitive, self-service Data Portal, and enhanced data integration and interoperability with external business intelligence tools.
The latest release addresses the needs of researchers and clinical scientists to make better data-informed decisions faster in translational and clinical studies. We were able to simplify data ingestion and access, extending analytical options for users, and addressing some of the key requirements of innovative biopharmaceutical R&D organizations.
Genedata Profiler 15.0 is the result of a development project in close collaboration with leading biopharma companies, such as Genmab (read more). The new cutting-edge features streamline the data analysis process, from ingestion, through fine-grained access to analytics, creating powerful insights.
The new Profiler Data Portal (watch the video) features an interactive, easy-to-use interface for secure self-service data access across all available studies and experiments. It allows user queries such as “Give me all data related to triple-negative breast cancer patients with a specific genomic mutation”.
Enhanced integration with data analytics tools for highly scalable & secure data analysis. Our analytics database connectors allow seamless, security controlled access & analysis of vast data sets in RStudio & BI tools. Integration with RStudio provides highly cost-efficient analysis by virtue of elastic computing using the Slurm scheduler.
Automated data ingestion workflows with a wizard-like web interface to load, structure, and quality-control data in Genedata Profiler. This allows preconfiguration of the workflows and automation of data ingestion and integration without losing the flexibility to handle diverse data types and changing requirements.
Improved interoperability with third-party tools to ingest, process, quality-control, and analyze data programmatically. This allows bioinformaticians to work with their preferred tools, while using Genedata Profiler as the central data management and security platform, ensuring full chain of custody in a GxP validated environment.
Improved platform resilience and secure cross-study collaboration. Single sign-on (SSO) support increases IT and employee security and productivity. Global study role auditing and enhanced study permissions ensure that the right users can access and use the right data.
(learn more about user access and permission)
To support our vision of transforming cancer treatment, we are excited to implement the Genedata Biopharma Platform as a central integrated data backbone to streamline the capture, integration, democratization, and analysis of increasingly complex and diverse data types across Genmab’s discovery and clinical workflows.
Hisham Hamadeh, Ph.D.
Vice President, Global Head of Data Sciences
Working closely with Genedata, we have generated a digital biomarker research platform that will enable Merck scientists to better utilize clinical and translational data to generate innovative ideas for new biomarkers and drug targets.
Joern Peter Halle
Head of Immuno-oncology and External Innovation
We are pleased to have found a reliable partner who provided us with expert knowledge in big multi-omics data analysis to accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions.
Andrés Hurtado-Lorenzo, Ph.D.
Senior Director of Translational Research
We chose Genedata Profiler because it is the end-to-end enterprise software able to harmonize our dispersed data analysis pipelines, enhancing our capacity to analyze large amounts of high-dimensional ‘omics data emerging from our rapidly growing number of translational and clinical research projects.
Department Manager of Clinical Pharmacology
As we expect our clinical and pre-clinical programs and pipeline to continue to grow, we look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients.
John de Kruif, Ph.D.
Chief Technology Officer